Immune checkpoint inhibitors (ICI) have shown clinical activity in advanced melanoma with significant survival benefits and response rates of 19% for the anti-CTLA-4 antibody ipilimumab and 36–44% for the anti-PD-1 antibodies nivolumab and pembrolizumab [36]. Here, PDCD1 is linked to melanoma.